FDA Votes In Favor Of Pfizer's Maternal RSV Vaccine To Prevent Disease In Infants
Portfolio Pulse from Vandana Singh
The FDA has voted in favor of Pfizer's maternal RSV vaccine candidate, RSVpreF, supporting its efficacy and safety. If approved, it could become the first maternal vaccine against the virus. Analysts estimate the market for RSV vaccines to surpass $10 billion by 2030.
May 19, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA has voted in favor of Pfizer's maternal RSV vaccine candidate, RSVpreF, supporting its efficacy and safety. If approved, it could become the first maternal vaccine against the virus.
The FDA's positive vote on Pfizer's RSV vaccine candidate indicates strong support for its efficacy and safety. If approved, it could become the first maternal vaccine against the virus, potentially opening up a significant market opportunity for Pfizer. This news is likely to have a positive short-term impact on Pfizer's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100